The collaboration will use single-cell and spatial biology platforms to identify biomarkers that predict treatment response in solid tumors.
10x Genomics and Lausanne University Hospital have entered a multi-year research collaboration to advance diagnostic applications of single-cell and spatial technologies in oncology.
The study intends to use the 10x Genomics Flex Apex and Xenium platforms, with plans to expand to the Atera platform, to examine tumor samples from patients with advanced cancer. These patients are currently undergoing a detailed evaluation by a clinical molecular tumor board. The research aims to identify clinically relevant biomarkers that may help predict treatment response and cancer prognosis, while supporting the development of new diagnostics.
The study is expected to include hundreds of patients across multiple solid tumor types, including non-small cell lung cancer, breast cancer, bladder cancer, and melanoma. Researchers plan to integrate single-cell and spatial biology data with clinical outcomes to better understand mechanisms of response and resistance across various therapeutic approaches, such as antibody-drug conjugates, bispecific antibodies, and immune checkpoint inhibitors.
“This collaboration brings together complementary expertise in spatial biology, pathology, computational artificial intelligence and clinical precision oncology to address one of the biggest challenges in cancer care: predicting which patients will benefit from treatment,” says Raphael Gottardo, professor and director of the Biomedical Data Science Center, Lausanne University Hospital, in a release. “Together, we aim to discover clinically actionable biomarkers that improve patient selection and bring more precise treatment decisions closer to routine clinical care.”
The collaboration also intends to investigate how these single-cell and spatial technologies can be deployed clinically alongside current standard-of-care assays. The project is expected to generate a multimodal resource that integrates data to enable the discovery of biomarkers for treatment response and resistance.
Furthermore, the teams plan to evaluate how these biomarkers could be incorporated into future clinical reporting frameworks to support personalized treatment planning and decision-making by molecular tumor boards.
“The promise of precision oncology depends on understanding the biology that helps determine which therapies are most likely to benefit a given patient,” says Serge Saxonov, co-founder and CEO of 10x Genomics, in a release. “We believe single cell and spatial technologies provide a fundamentally richer view of the biology within tumors and their microenvironment, creating opportunities to discover biomarkers that can help guide treatment decisions and enable future diagnostic approaches in cancer care.”
ID 107086721 © Toxawww | Dreamstime.com
